Cipla’s Yurpeak gains ground beyond metros as GLP‑1 market accelerates

Cipla

• Yurpeak sales hit Rs.18.8 crore in Jan 2026, up from Rs.14 crore
• Cipla's wide rollout boosts access in tier-2/3 and metro cities

Did our AI summary help?

Cipla’s tirzepatide brand Yurpeak is accelerating faster than many anticipated, riding a wave of demand from both major metros and fast‑urbanising smaller cities.

Barely weeks after launch, booking Rs 18.8 crore in January 2026, up from Rs.14 crore in December, as the company leans on a wide field force and deeper tier‑2/3 penetration. That makes Yurpeak second best selling new launch in January.

Meanwhile, Eli Lilly’s Mounjaro remains the category’s benchmark with Rs.112.6 crore in January sales, underscoring its early‑mover advantage. Cipla launched Yurpeak - as the second tirzepatide brand in December 2025 in collaboration with Eli Lilly for the management of type 2 diabetes and obesity.

Yurpeak’s success so far stems from Cipla’s unusually wide and rapid commercial rollout. The company has focused heavily on tier‑2 and tier‑3 markets even while building presence in India’s largest cities. While the therapy is priced at the same level as Mounjaro (approximately Rs.13,000–Rs.27,500/month depending on dosage), but Cipla’s reach is expected to make it more accessible.

Strong uptake is visible across Mumbai, Bengaluru, Delhi, Chennai, Hyderabad, Indore and Pune, as well as smaller but fast‑growing centres such as Cannanore, Vijayawada, Aurangabad, Surat, Faizabad and Mangalore—locations where prescriber activation and distribution density are translating into early conversions.

The broader tirzepatide market has already scaled Rs.746 crore on a MAT January 2026 basis, reflecting how next‑gen anti‑diabetics are reshaping India’s chronic‑care stack.

Achin Gupta, Cipla’s Managing Director and Global CEO Designate , in a post earnings media calls said the company holds “full, all‑over‑India marketing rights for Yurpeak… covering pretty much all of the country with obviously more focus on outside of metros.”

He maintains that semaglutide generics—expected to intensify metabolic‑care competition—will expand, not cannibalize, demand: “We believe it will open up a new segment… Tirzepatide has dual action GLP and GIP, which we believe makes it a preferred option.”

The demand surge is also being powered by a shift in patient behaviour, particularly outside India’s top cities.

Dr. Rajiv Kovil, Diabetologist and Director at Zandra Healthcare, observes a structural change:

“Across India, especially in Tier 1 and rapidly evolving Tier 2 cities, we are witnessing a clear shift in how obesity is perceived. Patients are no longer viewing excess weight as a cosmetic concern but as a chronic, relapsing disease… Awareness about modern weight‑loss therapies, including GLP‑1 based medications, has increased significantly.”

He adds that aspiration and health literacy are rising sharply in smaller cities, where patients are “actively seeking scientific solutions… asking informed questions about safety, long‑term outcomes, and sustainability… wanting structured, evidence‑based care, not cosmetic shortcuts.”

Analysts share this optimism. Nuvama estimates Rs.370 crore in FY27 revenue for Yurpeak, citing Cipla’s scale, distribution reach and the GLP‑1 category’s early traction.